Asklepios BioPharmaceutical Inc., better known as AskBio, has received a $235 million investment to augment and accelerate growth of its business.

The company partnered with TPG Capital, an alternative asset group that has invested in Airbnb and Spotify, and Vida Ventures, a life sciences investment firm, to make up the lump sum of the financing.

TPG Capital and Vida Ventures are receiving a minority stake in AskBio for their joint contributions that account for $225 million of the total investment. AskBio’s founders and board members will co-invest the remaining $10 million.

“AskBio is a very special company, operating in one of the most innovative and strategically important sectors of the pharmaceutical industry today,” said John Schilling, partner at TPG Capital.

AskBio specializes in providing gene therapy services for “underserved patient populations with rare and generally untreatable genetic disorders.”

Jude Samulski, AskBio president and chief scientific officer, and Ask Bio CEO Sheila Mikhail co-founded the company in 2001 at the Gene Therapy Center at UNC-Chapel Hill.

“I am excited to partner with TPG and Vida to catalyze the next generation of gene therapy innovation and translate discovery into life-changing therapeutics,” said Samulski in a statement.

AskBio stated that the investment will help the company drive long-term growth by providing additional capital to enhance manufacturing capabilities and capacities and to advance and expand clinical trials.

The release can be found here.